感恩并传承丨广东省人民医院吴一龙教授团队-中国肺癌原创临床研究阶段汇总
读书笔记丨感恩并传承CTONG-中国肺癌原创临床研究
CTONG-TALK | 带你走进CTONG的世界
CTONG-TALK｜CTONG 1509研究开启EGFR突变NSCLC联合治疗新模式
CTONG-TALK｜CTONG 1103——讲述新辅助靶向治疗的故事
携手共赢丨广东省人民医院吴一龙教授团队代表性论著阶段汇总
读书笔记丨历届肺癌高峰论坛专家共识汇总
江浙沪地区历届重要肺癌论坛汇总（长三角地区肺癌论坛系列）
传承与发展丨长三角肺癌代表性论著阶段汇总
读书笔记丨长三角肺癌之光-中国肺癌原创临床研究阶段汇总
长三角肺癌协作组青年博士团队组织框架介绍
齐聚浙江嘉兴，长三角肺癌再续新篇章——浙江省基层肺癌协作组成立
走进中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房
Lancet Oncol
Lancet Oncol Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Yi-long Wu (2011)
Lung Cancer
Lung Cancer Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study Yi-long Wu (2012)
Chin J Cancer Res
Chin J Cancer Res Nedaplatin/Gemcitabine versus Carboplatin/Gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial Yi-long Wu (2012)
Ann Oncol
Ann Oncol Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and a symptomatic brain metastases: a phase II study (CTONG-0803) Yi-long Wu (2013)
Lancet Oncol
Lancet Oncol Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Yi-long Wu (2013)
Lung Cancer
Lung Cancer A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805) Yi-long Wu (2013)
Lancet Oncol
Lancet Oncol Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi-long Wu (2014)
Lung Cancer
Lung Cancer Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer Yi-long Wu (2014)
Ann Oncol
Ann Oncol Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial Yi-long Wu (2014)
Lancet Oncol
Lancet Oncol Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Yi-long Wu (2014)
J Hematol Oncol
J Hematol Oncol Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status Yi-long Wu (2015)
Ann Oncol
Ann Oncol Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Yi-long Wu (2015)
Ann Oncol
Ann Oncol First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Yi-long Wu (2015)
J Hematol Oncol
J Hematol Oncol Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Yi-long Wu (2016)
Lung Cancer
Lung Cancer Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinumin the first-line treatment of advanced non-small-cell lung cancer Yi-long Wu (2016)
Lancet Respir Med
Lancet Respir Med Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial Yi-long Wu (2016)
Br J Cancer
Br J Cancer A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations Yi-long Wu (2016)
Lancet Oncol
Lancet Oncol Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi-long Wu (2016)
Br J Cancer
Br J Cancer EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 Yi-long Wu (2016)
Lung Cancer
Lung Cancer Efficacy according to blind independent central review: post-hoc analyses from the Phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Yi-long Wu (2017)
N Engl J Med
N Engl J Med Osimertinib or platinum-pemetrexedin EGFR T790M-positive lung cancer Yi-long Wu (2017)
Lancet Respir Med
Lancet Respir Med Detection of EGFR mutations in plasma circulating tumor DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial Yi-long Wu (2018)
J Clin Oncol
J Clin Oncol Improvement in overall survival in a randomized study that compared Dacomitinib with Gefitinib in patients with advanced non-small-cell lung cancer and EGFR activating mutations Yi-long Wu (2018)
J Clin Oncol
J Clin Oncol Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor therapy in patients with EGFR-mutated, MET Factor-Dysregulated non-small-cell lung cancer Yi-long Wu (2018)
J Clin Oncol
J Clin Oncol Phase II study of Crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer Yi-long Wu (2018)
J Thorac Oncol
J Thorac Oncol Results of PROFILE 1029, a phase III comparison of first-line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer Yi-long Wu (2018)
J Thorac Oncol
J Thorac Oncol The unique spatial-temporal treatment failure patterns of adjuvant Gefitinib Therapy: A Post Hoc analysis of the ADJUVANT Trial (CTONG 1104) Yi-long Wu (2018)
Eur J Cancer
Eur J Cancer A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002) Yi-long Wu (2018)
Lung Cancer
Lung Cancer Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies Yi-long Wu (2018)
Lung Cancer
Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial Yi-long Wu (2018)
Lung Cancer
Lung Cancer EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer Yi-long Wu (2018)
Patient
Patient Does EGFR mutation type influence patient-reported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large, phase III studies comparing Afatinib with chemotherapy (LUX-Lung 3 and LUX-Lung 6) Yi-long Wu (2018)
Onco Targets Ther
Onco Targets Ther Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial Yi-long Wu (2018)
EBioMedicine
EBioMedicine Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosinekinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial Yi-long Wu (2019)
Am J Clin Oncol
Am J Clin Oncol Efficacy and safety of Gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with First-line Gefitinib followed by second-line chemotherapy A single-arm, prospective, multicenter phase II study (RE-CHALLENGE, CTONG1304) Yi-long Wu (2019)
J Clin Oncol
J Clin Oncol Erlotinib versus Gemcitabine plus Cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-celllung cancer (EMERGING-CTONG 1103): A randomized phase II study Yi-long Wu (2019)
J Thorac Oncol
J Thorac Oncol Nivolumab versus Docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial Yi-long Wu (2019)
Lung Cancer
Lung Cancer Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study Yi-long Wu (2019)
Lung Cancer
Lung Cancer Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib：Results from ASCEND-6 Yi-long Wu (2020)
N Engl J Med
N Engl J Med Osimertinib in resected EGFR-mutated non-small-cell lung cancer Yi-long Wu (2020)
Lancet Respir Med
Lancet Respir Med Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Yi-long Wu (2020)
J Clin Oncol
J Clin Oncol Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutat NSCLC: Final overall survival analysis of CTONG1104 phase III trial Yi-long Wu (2020)
Ann Oncol
Ann Oncol Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small cell lung cancer：an open-label，randomized，multicenter，phase III trial Yi-long Wu (2020)
Lung Cancer
Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Yi-long Wu (2020)
Invest New Drugs
Invest New Drugs A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer Yi-long Wu (2020)
Int J Cancer
Int J Cancer Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study Yi-long Wu (2021)
Drugs
Drugs Updated overall survival in a randomized study comparing Dacomitinib with Gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations Yi-long Wu (2021)
Clin Lung Cancer
Clin Lung Cancer Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI: Analysis of a phase III randomized clinical trial (CTONG 0901) Yi-long Wu (2021)